Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesDividends payablesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Envoy Medical (COCH) Liabilities and Shareholders Equity (2022 - 2025)

Historic Liabilities and Shareholders Equity for Envoy Medical (COCH) over the last 4 years, with Q3 2025 value amounting to $8.2 million.

  • Envoy Medical's Liabilities and Shareholders Equity fell 1294.03% to $8.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.0 million, marking a year-over-year increase of 2164.82%. This contributed to the annual value of $11.5 million for FY2024, which is 3949.95% up from last year.
  • Latest data reveals that Envoy Medical reported Liabilities and Shareholders Equity of $8.2 million as of Q3 2025, which was down 1294.03% from $9.9 million recorded in Q2 2025.
  • In the past 5 years, Envoy Medical's Liabilities and Shareholders Equity registered a high of $427.8 million during Q3 2022, and its lowest value of $2.6 million during Q4 2022.
  • For the 4-year period, Envoy Medical's Liabilities and Shareholders Equity averaged around $97.9 million, with its median value being $10.4 million (2025).
  • Data for Envoy Medical's Liabilities and Shareholders Equity shows a peak YoY increase of 22359.15% (in 2023) and a maximum YoY decrease of 9504.1% (in 2023) over the last 5 years.
  • Quarter analysis of 4 years shows Envoy Medical's Liabilities and Shareholders Equity stood at $2.6 million in 2022, then surged by 223.59% to $8.3 million in 2023, then soared by 39.5% to $11.5 million in 2024, then decreased by 29.1% to $8.2 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $8.2 million for Q3 2025, versus $9.9 million for Q2 2025 and $10.4 million for Q1 2025.